Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Osteitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Osteitis. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-004682-24 Sponsor Protocol Number: DC0071BB405 Start Date*: 2015-04-27
    Sponsor Name:Institut de Recherche Pierre Fabre - Centre de R&D Pierre Fabre
    Full Title: Efficacy of DC071 mouthwash (0,2 % chlorhexidine digluconate) in peri-surgical care for preventing alveolar osteitis after third molar extraction. Prospective, multicenter, randomised, double-blin...
    Medical condition: Prevention of alveolar osteitis after third molar extraction
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10066995 Alveolar osteitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) FR (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-007024-34 Sponsor Protocol Number: Stom2009 Start Date*: 2009-12-28
    Sponsor Name:General Teaching Hospital
    Full Title: Treatment of alveolar osteitis using ozonated water
    Medical condition: Complication after tooth extraction - alveolar osteitis (dry socket). There is no causal treatment of alveolar osteitis. That’s why symptomatic therapy is used. Disinfectants are the most important...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013787 Dry socket LLT
    12.0 10013787 Dry socket LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005647-14 Sponsor Protocol Number: 07/cmc/4088e Start Date*: 2009-03-16
    Sponsor Name:Cardiff University
    Full Title: Gamma Delta T Cells and their role in the acute phase reaction to intravenous bisphosphonates
    Medical condition: Patients with osteoporosis or Paget's disease of bone
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031282 Osteoporosis LLT
    9.1 10033362 Paget's disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002898-12 Sponsor Protocol Number: CZOL446K2418 Start Date*: 2008-10-24
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: Estudio abierto de re-tratamiento con Aclasta® en pacientes que han presentado recaída de la Enfermedad ósea de Paget y que participaron en los estudios de registro CZOL446K2304 y CZOL446K2305.
    Medical condition: Tratamiento para la Enfermedad ósea de Paget
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033363 Paget's disease of bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-005667-34 Sponsor Protocol Number: G0701625 Start Date*: 2009-01-16
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Randomised Trial of Genetic Testing and Targeted Zoledronic acid therapy to Prevent SQSTM1 Mediated Paget's Disease (Zoledronate in the Prevention of Paget's).
    Medical condition: Paget's disease of the bone (PDB)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10033363 Paget's disease of bone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed) IE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2006-003549-18 Sponsor Protocol Number: 004/001 Start Date*: Information not available in EudraCT
    Sponsor Name:Cliniques Universitaires SAINT-LUC
    Full Title: REDUCTION OF BONE MORBIDITY USING AN ORAL BISPHOSPHONATE IN FIBROUS DYSPLASIA OF BONE (PROFIDYS Trial)
    Medical condition: Fibrous dysplasia •Study I: patients with fibrous dysplasia of bone, with bone pain intensity above 3 on a visual analogical scale from 0 to 10. •Study II: patients with fibrous dysplasia of bone...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10016664 Fibrous dysplasia of bone PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000555-93 Sponsor Protocol Number: ARIAA Start Date*: 2014-08-20
    Sponsor Name:University Hospital Erlangen
    Full Title: Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive Arthralgia
    Medical condition: Patients with ACPA (anti citrullinated peptide antibodies) positive arthralgia and OMERACT RAMRIS synovitis (synovialitis or tenosynovitis) or osteitis but without clinical arthritis, defined by jo...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10003239 Arthralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024282-41 Sponsor Protocol Number: 2010.648 Start Date*: 2012-12-05
    Sponsor Name:Hospices Civils de Lyon
    Full Title: TRAITEMENT DE LA DYSPLASIE FIBREUSE DES OS CHEZ LES PATIENTS NON REPONDEURS AUX BISPHOSPHONATES PAR LE TOCILIZUMAB. L’ESSAI TOCIDYS
    Medical condition: dysplasie fibreuse des os
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10016664 Fibrous dysplasia of bone PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000902-31 Sponsor Protocol Number: ECACOR19 Start Date*: 2019-09-05
    Sponsor Name:OMEQUI
    Full Title: Healing efficacy after impacted mandibular third molar surgery with the use of autologous platelet-rich fibrin: a randomized controlled clinical study
    Medical condition: If the addition of L-PRF reduces postoperative pain and inflammation, as well as complications, after extraction of lower third molars
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003606-14 Sponsor Protocol Number: SCH-2013 Start Date*: 2017-01-31
    Sponsor Name:Sheffield Children's NHS Foundation Trust
    Full Title: Do bisphosphonates alter the skeletal response to mechanical stimulation in children with osteogenesis imperfecta?
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005358-27 Sponsor Protocol Number: ASMAB1 Start Date*: 2006-07-12
    Sponsor Name:University Hospital of North Staffordshire
    Full Title: Efficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance imaging study
    Medical condition: Ankylosing spondylitis (AS) is an inflammatory condition primarily affecting the spine. The disease may remain symptomatic and progressive life-long. It is part of the family of spondyloarthropat...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004734-15 Sponsor Protocol Number: EBio Start Date*: 2019-06-03
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: EBIO – Enthesitis biopsy study
    Medical condition: Psoriatic arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001068-27 Sponsor Protocol Number: 2020-001068-27 Start Date*: 2020-12-01
    Sponsor Name:Leiden University Medical Center
    Full Title: Pamidronate for pain in adult chronic nonbacterial osteitis (PAM-CNO): a randomized, double-blind, placebo-controlled trial
    Medical condition: Chronic nonbacterial osteitis (CNO) in adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001465-41 Sponsor Protocol Number: CBPS804A2201 Start Date*: 2011-07-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label intra-patient dose escalation study with an untreated reference group to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of multiple infusions of B...
    Medical condition: Patients with previously established diagnosis of osteogenesis imperfecta (OI). OI is a rare genetic disorder of the connective tissue characterized by bone fragility and reduced bone mass. OI comp...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004122-28 Sponsor Protocol Number: RR13/10782 Start Date*: 2015-03-02
    Sponsor Name:The Leeds Teaching Hospitals NHS Trust
    Full Title: An investigator‐initiated double‐blind, parallel‐group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes: th...
    Medical condition: Adult patients with a diagnosis of Psoriatic Arthritis(PsA), (Caspar criteria) of less than 24-month duration.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004604-19 Sponsor Protocol Number: CAR-ERA Start Date*: 2014-08-06
    Sponsor Name:Heinrich-Heine-Universität Düsseldorf
    Full Title: Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rh...
    Medical condition: patients with early progressive rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004859 10066578 Progression of rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003439-41 Sponsor Protocol Number: VX12-509-103 Start Date*: 2013-04-11
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VX 509 using Magnetic Resonance Imaging and Arthroscopic Biopsi...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) DK (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002622-39 Sponsor Protocol Number: PEDFOI Start Date*: 2015-11-18
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Experimental Study Protocol on Treatment with plasma transfusions in Patients affected by type VI Osteogenesis Imperfecta
    Medical condition: type VI Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004972-74 Sponsor Protocol Number: 20160227 Start Date*: 2020-09-15
    Sponsor Name:Amgen Inc.
    Full Title: An Open-label, Ascending Multiple dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents With Osteogenesis Imperfecta
    Medical condition: Osteogenesis imperfecta (OI) is a group of genetic skeletal disorders characterized by increased bone fragility, low bone mass , and increased bone turnover contributing to osteoporosis, fracture...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GR (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000745-21 Sponsor Protocol Number: P1200_12 Start Date*: 2012-12-10
    Sponsor Name:Schriners Hospitals for Children
    Full Title: An international, multicenter, open-label, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta
    Medical condition: Children suffering from severe Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 11:07:14 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA